ATE538136T1 - Antikörper gegen connective tissue growth factor - Google Patents

Antikörper gegen connective tissue growth factor

Info

Publication number: ATE538136T1
Authority: AT; Austria
Prior art keywords: growth factor; antibodies against; connective tissue; tissue growth; antibodies
Prior art date: 2003-06-04

Application number

AT04753822T

Other languages

English (en)

Inventor

Ai Lin

Thomas Neff

Noelynn Oliver

William Usinger

Qingjian Wang

David Yeowell

Original Assignee

Fibrogen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-04

Filing date

2004-06-02

Publication date

2012-01-15

2004-06-02 Application filed by Fibrogen Inc filed Critical Fibrogen Inc

2012-01-15 Application granted granted Critical

2012-01-15 Publication of ATE538136T1 publication Critical patent/ATE538136T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Cardiology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)

AT04753822T 2003-06-04 2004-06-02 Antikörper gegen connective tissue growth factor ATE538136T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US47559803P	2003-06-04	2003-06-04
US10/858,186 US7405274B2 (en)	2003-06-04	2004-06-01	Connective tissue growth factor antibodies
PCT/US2004/017080 WO2004108764A2 (en)	2003-06-04	2004-06-02	Connective tissue growth factor antibodies

Publications (1)

Publication Number	Publication Date
ATE538136T1 true ATE538136T1 (de)	2012-01-15

Family

ID=33493433

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04753822T ATE538136T1 (de)	2003-06-04	2004-06-02	Antikörper gegen connective tissue growth factor

Country Status (16)

Country	Link
US (9)	US7405274B2 (de)
EP (3)	EP1631591B1 (de)
JP (2)	JP5624707B2 (de)
KR (1)	KR101244113B1 (de)
CN (2)	CN1829740B (de)
AT (1)	ATE538136T1 (de)
AU (1)	AU2004245514B2 (de)
BR (1)	BRPI0410963B8 (de)
CA (1)	CA2526509C (de)
DK (1)	DK1631591T3 (de)
ES (1)	ES2379662T3 (de)
IL (1)	IL172328A (de)
NO (1)	NO336451B1 (de)
NZ (1)	NZ543522A (de)
RU (1)	RU2330861C2 (de)
WO (1)	WO2004108764A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7115390B1 (en) *	1998-12-14	2006-10-03	Fibrogen, Inc.	Connective tissue growth factor fragments and methods and uses thereof
MXPA01005949A (es) *	1998-12-14	2002-09-18	Univ Miami	Fragmentos de factor de crecimiento de tejido conectivo y metodos y usos de los mismos.
CA2555789A1 (en)	2004-02-11	2005-08-25	Fibrogen, Inc.	Ctgf as target for the therapy of diabetic nephropathy
MXPA06012576A (es) *	2004-04-28	2007-01-31	Fibrogen Inc	Tratamientos para cancer pancreatico.
EP1891109A1 (de) *	2005-05-05	2008-02-27	Fibrogen, Inc.	Therapien von herzkreislauferkrankungen
ATE507243T1 (de) *	2005-09-29	2011-05-15	Fibrogen Inc	Verfahren zur senkung des blutdrucks
JP2008295328A (ja) *	2007-05-30	2008-12-11	Fujifilm Corp	卵巣癌の検出方法、及び抑制方法
EP2342340A1 (de)	2008-09-22	2011-07-13	Rxi Pharmaceuticals Corporation	Rna-interferenz bei hautindikationen
RU2392960C1 (ru) *	2008-09-26	2010-06-27	Учреждение Российской академии медицинских наук Научный центр реконструктивной и восстановительной хирургии Сибирского отделения РАМН (НЦРВХ СО РАМН)	Способ коррекции плотности соединительной ткани
WO2010042202A1 (en) *	2008-10-07	2010-04-15	Fibrogen, Inc.	Methods for treatment of podocyte injury
WO2010042201A1 (en) *	2008-10-07	2010-04-15	Fibrogen, Inc.	Methods for treatment of focal segmental glomerulosclerosis
EP2221387A1 (de) *	2009-02-19	2010-08-25	Université de la Méditerranée	Fibroseanfälligkeitsgen und Verwendungen davon
US20110110953A1 (en) *	2009-06-29	2011-05-12	Dennis Keith Bishop	Compound and method for treatment of chronic transplant rejection
EP2448971A1 (de) *	2009-07-02	2012-05-09	Fibrogen, Inc.	Verfahren zur behandlung von muskeldystrophie
WO2011056234A1 (en)	2009-11-06	2011-05-12	Fibrogen, Inc.	Treatment for radiation-induced disorders
US9095504B2 (en)	2010-03-24	2015-08-04	Rxi Pharmaceuticals Corporation	RNA interference in ocular indications
CA2794189C (en)	2010-03-24	2022-01-11	Rxi Pharmaceuticals Corporation	Rna interference in dermal and fibrotic indications
WO2012061811A2 (en)	2010-11-05	2012-05-10	Fibrogen, Inc.	Treatment method for lung remodeling diseases
WO2012100262A1 (en)	2011-01-21	2012-07-26	Fibrogen, Inc.	Therapeutic method using anti - ctgf antibody
US20140065162A1 (en) *	2011-11-08	2014-03-06	Fibrogen, Inc.	Compositions and Methods for Treating Brain Tumors
JP6040943B2 (ja) *	2011-12-22	2016-12-07	アステラス製薬株式会社	新規抗ヒトｃｔｇｆ抗体
JP6187960B2 (ja) *	2012-01-20	2017-08-30	日本製粉株式会社	がんの治療又は予防剤
WO2013148159A1 (en) *	2012-03-30	2013-10-03	Fibrogen Inc	Therapeutic methods for peritoneal carcinomatosis
US9480449B2 (en) *	2012-05-03	2016-11-01	Fibrogen, Inc.	Methods for treating idiopathic pulmonary fibrosis
KR102221499B1 (ko) *	2013-09-26	2021-03-02	갈데르마 소시에떼아노님	위축성 피부 흉터를 치료하기 위한 프로스타글라딘 F2α 및 그 유사체
US9631013B2 (en)	2014-01-28	2017-04-25	Fibrogen, Inc.	Therapeutic method for pancreatic cancer
EP3188799B1 (de)	2014-09-05	2022-07-06	Phio Pharmaceuticals Corp.	Verfahren zur behandlung von alterung und hauterkrankungen mit auf tyr oder mmp1 gerichteten nukleinsäuren
CN104740628B (zh) *	2015-02-12	2017-09-26	西安交通大学医学院第一附属医院	用于治疗肝纤维化的结缔组织生长因子嵌合疫苗及其应用
CN107922485A (zh)	2015-06-15	2018-04-17	斯坦福大学托管董事会	诊断和治疗情绪障碍的方法
EP3386544B1 (de)	2015-12-10	2020-11-25	Fibrogen, Inc.	Verfahren zur behandlung von motoneuronenerkrankungen
JP2019517274A (ja) *	2016-06-13	2019-06-24	ザユニバーシティオブノースカロライナアットチャペルヒルＴｈｅＵｎｉｖｅｒｓｉｔｙＯｆＮｏｒｔｈＣａｒｏｌｉｎａＡｔＣｈａｐｅｌＨｉｌｌ	最適化されたｃｌｎ１遺伝子および発現カセットおよびそれらの使用
JP7167059B2 (ja)	2017-04-19	2022-11-08	フィオファーマシューティカルズコーポレーション	核酸化合物の局所送達
IL275273B2 (en)	2017-12-15	2024-09-01	Medizinische Hochschule Hannover	Improved compound for treatment of heart failure
EP4365299A3 (de) *	2018-05-17	2024-08-07	Olives Biotherapeutics Inc.	Pharmazeutische zusammensetzung mit ccn5 als wirkstoff zur vorbeugung oder behandlung von netzhauterkrankungen
JP7542799B2 (ja) *	2018-07-04	2024-09-02	京都府公立大学法人	眼組織の線維化抑制用組成物
CN109402127B (zh) *	2018-09-29	2021-12-10	复旦大学附属眼耳鼻喉科医院	一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
CN109824777A (zh) *	2019-03-15	2019-05-31	辽宁何氏医学院	一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用
US20200369759A1 (en)	2019-05-23	2020-11-26	Fibrogen, Inc.	Methods of treatment of muscular dystrophies
CA3142092A1 (en) *	2019-06-04	2020-12-10	Jiangsu Hengrui Medicine Co., Ltd.	Anti-connective tissue growth factor antibody and application thereof
EP3821946A1 (de) *	2019-11-12	2021-05-19	Université de Strasbourg	Monoklonale anti-claudin-1-antikörper zur prävention und behandlung von fibrotischen erkrankungen
CN115286713B (zh) *	2020-10-27	2024-07-23	温州医科大学	一种以结缔组织生长因子为靶点的全人源拮抗抗体及其应用
US20230416352A1 (en) *	2020-12-03	2023-12-28	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Pharmaceutical composition comprising anti-connective tissue growth factor antibody
CN115645525B (zh) *	2022-12-14	2023-04-14	北京大学第三医院（北京大学第三临床医学院）	Ctgf中和抗体在制备防治绝经后骨关节炎的药物中的应用
WO2024188179A1 (zh) *	2023-03-10	2024-09-19	上海济煜医药科技有限公司	一种靶向ctgf的抗体或其抗原结合片段及其应用
US12121561B1 (en)	2024-02-17	2024-10-22	King Faisal University	Composition for treating or preventing insulin resistance

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US587670A (en)		1897-08-03		Combined high-pressure throttle and reducing valve
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
EP1690935A3 (de)	1990-01-12	2008-07-30	Abgenix, Inc.	Bildung von xenogenen Antikörpern
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0590058B1 (de)	1991-06-14	2003-11-26	Genentech, Inc.	Humanisierter Heregulin Antikörper
US5770209A (en) *	1991-08-30	1998-06-23	University Of South Florida	Acceleration of wound healing using connective tissue growth factor
US5837258A (en) *	1991-08-30	1998-11-17	University Of South Florida	Induction of tissue, bone or cartilage formation using connective tissue growth factor
US5408040A (en)	1991-08-30	1995-04-18	University Of South Florida	Connective tissue growth factor(CTGF)
JPH07503132A (ja)	1991-12-17	1995-04-06	ジェンファーム　インターナショナル，インコーポレイティド	異種抗体を産生することができるトランスジェニック非ヒト動物
AU3536495A (en)	1994-09-15	1996-03-29	Fred Nordberg	Electric fence device
US5876730A (en)	1997-08-07	1999-03-02	Childrens Hospital Research Foundation	Heparin-binding growth factor (HBGF) polypeptides
JPH11180895A (ja) *	1997-09-12	1999-07-06	Masaharu Takigawa	血管新生阻害剤
JP4537507B2 (ja) *	1997-12-25	2010-09-01	アムジェンインコーポレイテッド	結合組織増殖因子に対するモノクローナル抗体及びその医薬用途
US6562618B1 (en)	1997-12-25	2003-05-13	Japan Tobacco, Inc.	Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
EP1112088B1 (de)	1998-09-08	2010-10-27	Henry Ford Health System	Verfahren zum Nachweis von Bindegewebswachstumsfaktor zur Diagnose von Nierkrankheiten
US6348329B1 (en)	1998-11-06	2002-02-19	Fibrogen, Inc.	Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
MXPA01005949A (es) *	1998-12-14	2002-09-18	Univ Miami	Fragmentos de factor de crecimiento de tejido conectivo y metodos y usos de los mismos.
US20040142325A1 (en) *	2001-09-14	2004-07-22	Liat Mintz	Methods and systems for annotating biomolecular sequences
WO2003024308A2 (en)	2001-09-18	2003-03-27	Fibrogen, Inc.	Methods of assaying connective tissue growth factor
AU2002366641A1 (en)	2001-12-11	2003-06-23	Fibrogen, Inc.	Methods for inhibiting ocular processes
US20190127456A1 (en) *	2017-10-31	2019-05-02	Fibrogen, Inc.	Methods of treating idiopathic pulmonary fibrosis

2004
- 2004-06-01 US US10/858,186 patent/US7405274B2/en not_active Expired - Lifetime
- 2004-06-02 CN CN2004800221456A patent/CN1829740B/zh not_active Expired - Lifetime
- 2004-06-02 EP EP04753822A patent/EP1631591B1/de not_active Expired - Lifetime
- 2004-06-02 EP EP10184591A patent/EP2322549A1/de not_active Withdrawn
- 2004-06-02 AU AU2004245514A patent/AU2004245514B2/en not_active Expired
- 2004-06-02 NZ NZ543522A patent/NZ543522A/en not_active IP Right Cessation
- 2004-06-02 CA CA2526509A patent/CA2526509C/en not_active Expired - Lifetime
- 2004-06-02 BR BRPI0410963A patent/BRPI0410963B8/pt not_active IP Right Cessation
- 2004-06-02 ES ES04753822T patent/ES2379662T3/es not_active Expired - Lifetime
- 2004-06-02 JP JP2006515028A patent/JP5624707B2/ja not_active Expired - Lifetime
- 2004-06-02 CN CN201310140880.8A patent/CN103539858A/zh active Pending
- 2004-06-02 EP EP10184854A patent/EP2338914A1/de not_active Withdrawn
- 2004-06-02 AT AT04753822T patent/ATE538136T1/de active
- 2004-06-02 DK DK04753822.8T patent/DK1631591T3/da active
- 2004-06-02 RU RU2005141492/13A patent/RU2330861C2/ru active
- 2004-06-02 WO PCT/US2004/017080 patent/WO2004108764A2/en not_active Ceased
- 2004-06-02 KR KR1020057022909A patent/KR101244113B1/ko not_active Expired - Lifetime
2005
- 2005-12-01 IL IL172328A patent/IL172328A/en active IP Right Grant
2006
- 2006-01-03 NO NO20060027A patent/NO336451B1/no unknown
2008
- 2008-06-09 US US12/157,262 patent/US7871617B2/en not_active Expired - Lifetime
2010
- 2010-11-10 US US12/927,243 patent/US20110091468A1/en not_active Abandoned
2012
- 2012-03-08 JP JP2012051770A patent/JP5753506B2/ja not_active Expired - Fee Related
- 2012-11-30 US US13/691,356 patent/US9034643B2/en not_active Expired - Lifetime
2015
- 2015-04-20 US US14/690,727 patent/US20160024198A1/en not_active Abandoned
2016
- 2016-05-25 US US15/164,615 patent/US20160257740A1/en not_active Abandoned
2018
- 2018-10-10 US US16/156,873 patent/US20190023778A1/en not_active Abandoned
2020
- 2020-09-08 US US17/014,852 patent/US20210230259A1/en not_active Abandoned
2022
- 2022-12-20 US US18/068,977 patent/US20240076364A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN103539858A (zh)	2014-01-29
NO20060027L (no)	2006-01-03
US20160024198A1 (en)	2016-01-28
US20140073047A1 (en)	2014-03-13
US7405274B2 (en)	2008-07-29
CA2526509C (en)	2013-08-06
KR101244113B1 (ko)	2013-03-18
RU2005141492A (ru)	2007-07-20
US20110091468A1 (en)	2011-04-21
CN1829740B (zh)	2013-05-29
BRPI0410963B8 (pt)	2021-05-25
US20090017043A1 (en)	2009-01-15
US20240076364A1 (en)	2024-03-07
ES2379662T3 (es)	2012-04-30
US7871617B2 (en)	2011-01-18
AU2004245514B2 (en)	2009-10-01
EP2322549A1 (de)	2011-05-18
WO2004108764A3 (en)	2005-03-03
DK1631591T3 (da)	2012-04-10
JP5753506B2 (ja)	2015-07-22
JP2007525194A (ja)	2007-09-06
IL172328A (en)	2012-01-31
KR20060030032A (ko)	2006-04-07
NZ543522A (en)	2008-06-30
US20160257740A1 (en)	2016-09-08
RU2330861C2 (ru)	2008-08-10
AU2004245514A1 (en)	2004-12-16
NO336451B1 (no)	2015-08-24
EP1631591B1 (de)	2011-12-21
JP5624707B2 (ja)	2014-11-12
US20210230259A1 (en)	2021-07-29
US9034643B2 (en)	2015-05-19
US20190023778A1 (en)	2019-01-24
EP2338914A1 (de)	2011-06-29
BRPI0410963A (pt)	2006-07-04
JP2012143239A (ja)	2012-08-02
EP1631591A2 (de)	2006-03-08
BRPI0410963B1 (pt)	2019-10-08
US20040248206A1 (en)	2004-12-09
CN1829740A (zh)	2006-09-06
WO2004108764A2 (en)	2004-12-16
HK1094336A1 (zh)	2007-05-04
CA2526509A1 (en)	2004-12-16

Publication	Publication Date	Title
DK1631591T3 (da)	2012-04-10	Antistoffer mod bindevævsvækstfaktor
WO2006014729A3 (en)	2007-01-04	Inhibitors of angiopoietin-like 4 protein, combinations, and their use
PL1615952T3 (pl)	2012-03-30	Sposoby leczenia chorób zapalnych z zastosowaniem środków specyficznie wiążących ludzką angiopoetynę-2
DE60233955D1 (de)	2009-11-19	Spezifische bindungsmittel von human angiopoietin-2
WO2003083041A3 (en)	2003-12-04	Cripto-specific antibodies
BRPI0307673A2 (pt)	2016-11-08	métodos de tratar doença vascular.
CY1111622T1 (el)	2015-10-07	Ανθρωποποιημενοι ανταγωνιστες anti-cmet
EA201001695A1 (ru)	2011-08-30	Применение эпотилона d для лечения заболеваний, связанных с тау-белком
WO2006121610A3 (en)	2007-01-25	Personal care compositions and methods for their use
DE602004020072D1 (de)	2009-04-30	1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
CY1112055T1 (el)	2015-11-04	Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
DE60327999D1 (de)	2009-07-30	Azolylaminoazine als inhibitoren von proteinkinasen
WO2006015263A3 (en)	2006-07-27	Lonidamine analogs
DK1411064T3 (da)	2008-03-25	Gangliosid-associerede rekombinante antistoffer og anvendelsen deraf i diagnosen og behandlingen af tumorer
NO20076241L (no)	2008-02-04	Terapier for vaskulaere sykdommer
BRPI0508700A (pt)	2007-08-07	uso de sns-595, composição farmacêutica, e, pó liofilizado
DE60206289D1 (de)	2006-02-02	Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
CY1109666T1 (el)	2014-08-13	Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
RU2003101434A (ru)	2004-07-27	Способ хирургического лечения рака периампулярной зоны
WO2003032899A3 (en)	2003-10-30	Methods and materials for targeting and affecting selected cells
DE602005027251D1 (de)	2011-05-12	Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen
DK1596879T3 (da)	2011-04-11	Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
DE602005013650D1 (de)	2009-05-14	Proteinhydrolysat zur behandlung von müdigkeit
NO20040815L (no)	2004-02-24	Anvendelse av antroquinoner i behandling av nyresykdom.
RU2003102394A (ru)	2004-08-10	Способ лечения гнойно-воспалительных заболеваний мягких тканей у детей